← All calls
biotechResolvedHit
FDA decision (PDUFA) — NUVL zidesamtinib
Will the FDA approve zidesamtinib (NUVL) on/around 2026-09-18? ROS1 NSCLC
premise not yet verified
EHIQ
50%
Market
—
Edge
—
—
Thesis
AUTO-SOURCED from the FDA catalyst calendar. NEEDS CALIBRATION before it goes to subscribers: set the EHIQ probability from endpoint quality (hard vs surrogate), trial design (RCT vs single-arm), and any prior CRL, then set digest_excluded=false. Placeholder prob 0.50 = max uncertainty.
Resolution
Outcome
—
Resolved
September 5, 2026
Opened
August 6, 2026
Expected resolution
July 22, 2026
Get an alert the moment this call resolves.
Every EHIQ call resolves on a date, in public. Subscribe free and we email you when this one grades, plus the weekly divergence leaderboard.